ArticleFrontiers in chemistry2018
Structure Based Virtual Screening Studies to Identify Novel Potential Compounds for GPR142 and Their Relative Dynamic Analysis for Study of Type 2 Diabetes.
Article in Frontiers in chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 55 citations in OpenAlex.
- Probing the dark chemical matter against PDE4 for the management of psoriasis using in silico, in vitro and in vivo approach.Molecular diversity · 2025Article
- Virtual screening of FOXO3a activators from natural product-like compound library.Molecular diversity · 2024Article
- Synthesis, characterization, and anti-cancer potential of novel p53-mediated Mdm2 and Pirh2 modulators: an integratedFrontiers in chemistry · 2024Article
- Computer-aided drug design for virtual-screening and active-predicting of main protease (MFrontiers in pharmacology · 2023Article
- Exploring potent aldose reductase inhibitors for anti-diabetic (anti-hyperglycemic) therapy: integrating structure-based drug design, and MMGBSA approaches.Frontiers in molecular biosciences · 2023Article
- Homology modeling, virtual screening, molecular docking, and dynamics studies for discoveringFrontiers in molecular biosciences · 2023Article
- Combination of Docking-Based and Pharmacophore-Based Virtual Screening Identifies Novel Agonists That Target the Urotensin Receptor.Molecules (Basel, Switzerland) · 2022Article
- Mind the Gap-Deciphering GPCR Pharmacology Using 3D Pharmacophores and Artificial Intelligence.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Structure-based pharmacophore modeling, virtual screening, and molecular dynamics simulation studies for identification ofFrontiers in medicine · 2022Article
- Computational Approaches for the Design of Novel Anticancer Compounds Based on Pyrazolo[3,4-d]pyrimidine Derivatives as TRAP1 Inhibitor.Molecules (Basel, Switzerland) · 2021Article
- Exploring safe and potent bioactives for the treatment of non-small cell lung cancer.3 Biotech · 2021Article
- Identification of immucillin analogue natural compounds to inhibitIn silico pharmacology · 2021Article
- Article
- Binding Mode Exploration of B1 Receptor Antagonists' by the Use of Molecular Dynamics and Docking Simulation-How Different Target Engagement Can Determine Different Biological Effects.International journal of molecular sciences · 2020Article
- Synergistic Effect of Chlorogenic Acid and Caffeic Acid with Fosfomycin on Growth Inhibition of a ResistantACS omega · 2020Article
- Antibacterial of Dibenzo-Drug design, development and therapy · 2020Article
- ImmtorLig_DB: repertoire of virtually screened small molecules against immune receptors to bolster host immunity.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
GPR142 (G protein receptor 142) is a novel orphan GPCR (G protein coupled receptor) belonging to "Class A" of GPCR family and expressed in β cells of pancreas. In this study, we reported the structure based virtual screening to identify the hit compounds which can be developed as leads for potential agonists. The results were validated through induced fit docking, pharmacophore modeling, and system biology approaches. Since, there is no solved crystal structure of GPR142, we attempted to predict the 3D structure followed by validation and then identification of active site using threading and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.